Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 USD | -6.09% | +2.37% | -62.39% |
May. 20 | Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index | CI |
May. 15 | Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000 | MT |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-62.39% | 1.48M | - | ||
+68.44% | 62.86B | B- | ||
-0.86% | 41.38B | B | ||
+45.66% | 40.38B | A | ||
-10.72% | 27.64B | C | ||
+14.45% | 26.46B | B- | ||
-21.95% | 18.9B | B | ||
+4.48% | 12.67B | B+ | ||
+24.54% | 12.27B | B+ | ||
+28.38% | 12.07B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- YTEN Stock
- Ratings Yield10 Bioscience, Inc.